High alloreactivity of low dose prophylactic donor lymphocyte infusions in acute leukemia patients transplanted with alemtuzumab
Biology of Blood and Marrow Transplantation, 08/08/2012
Liga M et al. – Leukemia patients who receive low doses of pDLIs after conditioning with alemtuzumab have a low relapse risk; however, this approach is associated with a relatively high incidence of severe graft–versus–host disease.
